Workflow
泽璟制药(688266.SH):注射用ZG006开展关键性临床试验并完成首例受试者入组

Core Viewpoint - Zai Lab (688266.SH) has received feedback from the Center for Drug Evaluation (CDE) regarding its investigational product, injectable ZG006, which has been granted conditional approval to initiate key clinical trials based on current safety and efficacy data [1] Group 1 - The CDE has agreed to allow Zai Lab to conduct critical clinical trials for injectable ZG006 based on the proposed target population [1] - The company is actively advancing the key clinical trials for injectable ZG006 in the designated indications and has recently completed the enrollment of the first subject [1]